TRIM21 deficiency promotes cell proliferation and tumorigenesis via regulating p21 expression in ovarian cancer

Tripartite motif-containing 21 (TRIM21) has been reported to have a cancer-promoting or anticancer effect in various tumors; however, its role in ovarian cancer (OC) remains to be elucidated. In this study, we explored the biological function of TRIM21 in OC progression and investigated the potentia...

Full description

Saved in:
Bibliographic Details
Published in:Bioengineered 2022-03, Vol.13 (3), p.6024-6035
Main Authors: Sun, Jieyun, Chen, Xintian, Ji, Xueying, Meng, Sen, Wang, Wenwen, Wang, Pengfei, Bai, Jin, Li, Zhongwei, Chen, Youguo
Format: Article
Language:English
Subjects:
Carcinogenesis - genetics
Carcinoma, Ovarian Epithelial
Cell Line, Tumor
Cell Movement - genetics
Cell Proliferation - genetics
Humans
migration
ovarian cancer
Ovarian Neoplasms - pathology
proliferation
Research Paper
TRIM21
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tripartite motif-containing 21 (TRIM21) has been reported to have a cancer-promoting or anticancer effect in various tumors; however, its role in ovarian cancer (OC) remains to be elucidated. In this study, we explored the biological function of TRIM21 in OC progression and investigated the potential mechanisms. We found that TRIM21 was remarkably decreased in OC tissues and cell lines compared with adjacent-cancerous tissues and normal ovarian epithelium cell. Decreased expression of TRIM21 in OC patients was significantly correlated with shorter overall and disease-specific survival by The Cancer Genome Atlas database (TCGA) analysis. Functional assays revealed that TRIM21 inhibited the migration and invasion of OC cells; and that TRIM21 also obviously impaired cell proliferation by inhibiting cell cycle progression in vitro and in vivo. Taken together, our results suggest that TRIM21 may be a promising biomarker and target for OC diagnosis and treatment.
ISSN:2165-5979
2165-5987
DOI:10.1080/21655979.2022.2042134